Cargando…
FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
Autores principales: | He, Xuemei, Wang, Manni, Wu, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032849/ https://www.ncbi.nlm.nih.gov/pubmed/33837193 http://dx.doi.org/10.1038/s41392-021-00590-8 |
Ejemplares similares
-
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016) -
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019) -
Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking
por: Liu, Luyan, et al.
Publicado: (2022) -
The Complex Association of FcγRIIb With Autoimmune Susceptibility
por: Verbeek, J. Sjef, et al.
Publicado: (2019) -
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
por: Hussain, Khiyam, et al.
Publicado: (2022)